Want to join the conversation?
$CAH's medical segment profit fell in FY15 from last year, primarily due to a decline in contribution from distribution of national brand products. This was partially offset by contributions from the strategic expansion of its portfolio of $CAH brand products and services, driven by acquisitions and targeted cost reductions.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.